Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Florence Namour
Observed names:
F Namour,
F. Namour,
Florence S. Namour,
Namour, F
Institution:
Galapagos (France)
Observed institution:
Galapagos (France)
ORCID:
0000-0002-8273-5451
Observed ORCID:
0000-0002-8273-5451
OpenAlex ID:
A5058667154
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
2015
·
Florence Namour
, Paul Matthias Diderichsen
, et al.
·
Clinical Pharmacokinetics
·
138
PDF
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
2017
·
Frédéric Vanhoutte
, Minodora Mazur
, et al.
·
Arthritis & Rheumatology
·
82
PDF
A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies
2016
·
Geert A. Cirkel
, Bojana Milojkovic Kerklaan
, et al.
·
Investigational New Drugs
·
63
PDF
Filgotinib: A Clinical Pharmacology Review
2022
·
Florence Namour
, Kacey Anderson
, et al.
·
Clinical Pharmacokinetics
·
61
PDF
GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy
2013
·
Anna Cozzoli
, Roberta Francesca Capogrosso
, et al.
·
Pharmacological Research
·
56
Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions
2016
·
Florence Namour
, Julie Desrivot
, et al.
·
Drug Metabolism Letters
·
55
Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects
2016
·
Florence Namour
, René Galien
, et al.
·
British Journal of Clinical Pharmacology
·
55
PDF
Identification of a 4-(Hydroxymethyl)diarylhydantoin as a Selective Androgen Receptor Modulator
2012
·
François Nique
, Séverine Hebbe
, et al.
·
Journal of Medicinal Chemistry
·
54
GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)
2019
·
Jane C. Davies
, Olivier Van de Steen
, et al.
·
Journal of Cystic Fibrosis
·
33
PDF
Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor
2018
·
Florence Namour
, Liesbeth Fagard
, et al.
·
British Journal of Clinical Pharmacology
·
30
PDF
Effects of Nandrolone in the Counteraction of Skeletal Muscle Atrophy in a Mouse Model of Muscle Disuse: Molecular Biology and Functional Evaluation
2015
·
Giulia Maria Camerino
, Jean-François Desaphy
, et al.
·
PLoS ONE
·
26
PDF
Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization
2014
·
Roland Blanqué
, Liên Lepescheux
, et al.
·
BMC Musculoskeletal Disorders
·
25
PDF
Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial
2012
·
René Westhovens
, Filip De Keyser
, et al.
·
Annals of the Rheumatic Diseases
·
23
PDF
The Relative Bioavailability and Effects of Food and Acid‐Reducing Agents on Filgotinib Tablets in Healthy Subjects
2019
·
Kacey Anderson
, Hao Zheng
, et al.
·
Clinical Pharmacology in Drug Development
·
21
OP0263 Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-term treatment of rheumatoid arthritis; results of a phase IIA trial
2012
·
F.P. Vanhoutte
, M. Mazur
, et al.
·
Annals of the Rheumatic Diseases
·
14
Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis
2019
·
Amit Taneja
, Julie Desrivot
, et al.
·
Clinical Pharmacokinetics
·
13
PDF
Pharmacokinetics, Safety, and Tolerability of GLPG0259, a Mitogen-Activated Protein Kinase-Activated Protein Kinase 5 (MAPKAPK5) Inhibitor, Given as Single and Multiple Doses to Healthy Male Subjects
2012
·
Florence Namour
, Frédéric P. Vanhoutte
, et al.
·
Drugs in R&D
·
12
ISABELA Studies: Plasma Exposure and Target Engagement Do Not Explain the Lack of Efficacy of Ziritaxestat in Patients with Idiopathic Pulmonary Fibrosis
2023
·
Amit Taneja
, Garrit Jentsch
, et al.
·
Clinical Pharmacology & Therapeutics
·
10
PDF
Ziritaxestat Drug–Drug Interaction with Oral Contraceptives: Role of SULT1E1 Inhibition
2022
·
Eric Helmer
, Negin Karimian
, et al.
·
Clinical Pharmacology & Therapeutics
·
9
PDF
Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects
2019
·
Kacey Anderson
, Yan Xin
, et al.
·
Clinical Pharmacology in Drug Development
·
9
Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers
1995
·
B Lenfant
, F Namour
, et al.
·
Antimicrobial Agents and Chemotherapy
·
9
Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”
2015
·
Florence Namour
·
Clinical Pharmacokinetics
·
8
PDF
AB0494 Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, Shows Similar PK and PD Profiles in Japanese and Caucasian Healthy Volunteers
2015
·
F. Namour
, B. Vayssière
, et al.
·
Annals of the Rheumatic Diseases
·
6
Drug–drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model
2023
·
Jeremy Perrier
, Virginie Gualano
, et al.
·
Clinical and Translational Science
·
5
PDF
Abstract 1568: GLPG0187, a small molecule integrin antagonist, shows good safety and decrease in CTX levels in single ascending dose study
2010
·
Giocondo Lorenzon
, Lien Gheyle
, et al.
·
Cancer Research
·
4
Show more works
View as search
Works count:
31
Citation count:
826
H-index:
14
I10-index:
18
Year
Topic
Type
